During a clinical trial, researchers found that CDK4/CDK6 inhibitor Verzenio may have a huge impact on women battling early stage breast cancer by decreasing the likelihood of the cancer returning.

CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...

CDK4/6 抑制剂联合内分泌治疗是 HR+/HER2- 晚期乳腺癌一线标准治疗方案[1,2]。随着多款 CDK4/6 抑制剂获批，越来越多 HR+/HER2- 晚期乳腺癌患者从治疗中获益。MONALEESA 系列研究探索了 CDK4/6 抑制剂瑞波 ...

This may be combined with a targeted drug such as a CDK4/6 inhibitor. If the initial hormone therapy stops working, another type can be tried, often along with a targeted drug such everolimus, a PI3K ...